Exelixis, Inc. today announced that the Exelixis-discovered compounds cabozantinib and cobimetinib will be the subjects of fourteen presentations at the upcoming 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting, which will be held from May 29 to June 2, 2015 in Chicago, Illinois, is expected to draw 30,000 oncology professionals from around the world.
Conferences
Next-generation sequencing increases actionable mutation detection in malignant melanoma
The use of next-generation sequencing in multi-gene targeted panel testing identified a considerable number of actionable mutations among patients with malignant melanoma, according to study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.
Durable response to T-VEC, GM-CSF linked to longer OS
Patients with unresected stage IIIB, stage IIIc or stage IV melanoma who achieved durable response to either talimogene laherparepvec or granulocyte-macrophage colony–stimulating factor demonstrated longer OS than those who did not achieve a durable response, according to study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.
Simultaneous treatment with ipilimumab, nivolumab improves outcomes in advanced melanoma
Patients with treatment-naive advanced melanoma who underwent simultaneous treatment with ipilimumab and nivolumab demonstrated longer PFS and a higher objective response rate than patients treated with ipilimumab alone, according to phase 2 study results presented at the American Association for Cancer Research Annual Meeting.